000 03207cam a2200493 i 4500
001 rnd000000000071220
003 RAND
005 20200811100911.0
008 011130s2001 caua b 000 0 eng d
020 _a0833031244
027 _aRAND/MR-1206-SANOFI
035 _a(Sirsi) a428042
037 _c$20.00
_fpaperback
040 _aCstmoR
_cCstmoR
043 _an-us---
050 4 _aRM301.25
_bP43 2001
245 0 0 _aPharmaceutical technology assessment for managed care :
_bcurrent practice and suggestions for improvement /
_cSamuel A. Bozzette ... [et al.].
264 1 _aSanta Monica, CA :
_bRAND,
_c2001.
300 _axi, 74 pages :
_billustrations ;
_c28 cm
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
337 _aunmediated
_bn
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
338 _avolume
_bnc
_2rdacarrier
500 _a"RAND Health."
504 _aIncludes bibliographical references (p. 71-74).
520 _aPowerful pharmaceuticals are of increasing clinical and economic importance to managed care organizations, which are often responsible for managing and paying for the increasing costs of pharmaceuticals. This creates an incentive for them to go beyond a focus on clinical effectiveness and safety to evaluate the cost-effectiveness of new drugs. This report describes the processes by which managed care organizations evaluate pharmaceutical technologies and suggests pathways for organizing improvement. It reviews current evaluation procedures, provides a framework for future evaluations, introduces evaluation approaches, and annotates resources for further research on each topic covered. The report finds that most managed care organizations have internal procedures for assessing new pharmaceutical technologies, but their medical directors commonly believe these procedures to be less rigorous and less systematic than are desirable. The decisionmaking framework outlined in the report and the techniques it incorporates describe an objective, reproducible process for assessing pharmaceutical technology in the managed care setting. It provides a "road map" that can help an organization expose hidden biases in current processes, build on its experiences with evaluation, and reduce the risk of illogical or poorly thought-through decisions.
530 _aAlso available on the internet via WWW in PDF format.
650 0 _aManaged care plans (Medical care)
_zUnited States.
650 0 _aMedical innovations
_zUnited States
_xEvaluation.
650 0 _aPharmaceutical technology
_xEffect of managed care on
_zUnited States.
650 0 _aPharmaceutical technology
_zUnited States
_xDecision making.
650 0 _aPharmaceutical technology
_zUnited States.
650 0 _aTechnology assessment
_zUnited States.
700 1 _aBozzette, Samuel A.
_eauthor.
700 1 _aD'Amato, Rebecca.
_eauthor.
700 1 _aMorton, Sally C.
_eauthor.
700 1 _aHarris, Katherine M.
_eauthor.
700 1 _aMeili, Robin.
_eauthor.
700 1 _aTaylor, Roger.
_eauthor.
710 2 _aRAND Health.
710 2 _aRand Corporation.
710 2 _aSanofi-Synethlabo Inc.
856 4 1 _yOnline Access
_uhttp://www.rand.org/publications/MR/MR1206/
999 _c599271
_d599271